The promise of precision cancer medicine is that we will be able to pair clinical and genomic data to provide better and more efficient treatment for cancer care.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Although the focus is on the optimal pairing of existing Food and Drug Administration-approved drugs with the patient׳s tumor, precision medicine should also help determine a patient׳s risk for disease progression. Precision medicine will hopefully also lead to improved molecular biomarkers. The specific needs for predictive biomarkers vary significantly based on cancer type. The chief aim for prostate cancer biomarker development is to help distinguish indolent from aggressive disease.
Rubin MA. Are you the author?
Institute for Precision Medicine of Weill Cornell Medical College and NewYork-Presbyterian Hospital, New York, NY; Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY; Department of Urology, Weill Cornell Medical College, New York, NY; Meyer Cancer Center of Weill Cornell Medical College and NewYork-Presbyterian Hospital, New York, NY.
Reference: Urol Oncol. 2014 Nov 20. pii: S1078-1439(14)00354-8.